Effects of human growth hormone in men over 60 years old.

Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE

The New England journal of medicine1 Jul 1990Cited by 808 (Europe PMC)

PMID2355952DOI10.1056/nejm199007053230101PepBankPUB-02355952

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In older men, human GH raised mean plasma IGF-I into the youthful range of 500 to 1500 U per liter.
In plain wordsIn older men, human GH raised plasma IGF-I from baseline into the reported youthful range.
Peptide
HGH (somatotropin)
Outcome
IncreasePlasma IGF-I
Study
n = 12
Comparator
Baseline period and untreated group 2
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
approximately 0.03 mg/kg three times a week · subcutaneous · six monthsAs given in this study (human).
Measurements
IGF-I
500 to 1500 U per liter
GH treatment
IGF-I
< 350 U per liter
group 2 (no treatment)
Source sentences
Summary
In group 1, the mean plasma IGF-I level rose into the youthful range of 500 to 1500 U per liter during treatment, whereas in group 2 it remained below 350 U per liter.
2 context sentences(design, population, supporting numbers)
Summary · context
To test this hypothesis, we studied 21 healthy men from 61 to 81 years old who had plasma IGF-I concentrations of less than 350 U per liter during a six-month base-line period and a six-month treatment period that followed.
Summary · context
During the treatment period, 12 men (group 1) received approximately 0.03 mg of biosynthetic human growth hormone per kilogram of body weight subcutaneously three times a week, and 9 men (group 2) received no treatment.
Report a problemFND-0235595201
02HumanNon-randomized trialEfficacy outcome
In older men, human GH increased lean body mass by 8.8 percent (P less than 0.05).
In plain wordsIn older men, human GH increased lean body mass from baseline by 8.8 percent.
Peptide
HGH (somatotropin)
Outcome
IncreaseLean body mass
Study
n = 12
Comparator
Baseline
Outcome group
Body composition · Musculoskeletal
Studied dose
approximately 0.03 mg/kg three times a week · subcutaneous · six monthsAs given in this study (human).
Measurements
Lean body mass change
8.8 percent
GH
Source sentences
Summary
The administration of human growth hormone for six months in group 1 was accompanied by an 8.8 percent increase in lean body mass, a 14.4 percent decrease in adipose-tissue mass, and a 1.6 percent increase in average lumbar vertebral bone density (P less than 0.05 in each instance).
2 context sentences(design, population, supporting numbers)
Summary · context
To test this hypothesis, we studied 21 healthy men from 61 to 81 years old who had plasma IGF-I concentrations of less than 350 U per liter during a six-month base-line period and a six-month treatment period that followed.
Summary · context
During the treatment period, 12 men (group 1) received approximately 0.03 mg of biosynthetic human growth hormone per kilogram of body weight subcutaneously three times a week, and 9 men (group 2) received no treatment.
Report a problemFND-0235595202
03HumanNon-randomized trialEfficacy outcome
In older men, human GH reduced adipose-tissue mass by 14.4 percent (P less than 0.05).
In plain wordsIn older men, human GH reduced fat mass from baseline by 14.4 percent.
Peptide
HGH (somatotropin)
Outcome
DecreaseAdipose-tissue mass
Study
n = 12
Comparator
Baseline
Outcome group
Body composition · Metabolic and weight
Studied dose
approximately 0.03 mg/kg three times a week · subcutaneous · six monthsAs given in this study (human).
Measurements
Adipose mass decrease
14.4 percent
GH
Source sentences
Summary
The administration of human growth hormone for six months in group 1 was accompanied by an 8.8 percent increase in lean body mass, a 14.4 percent decrease in adipose-tissue mass, and a 1.6 percent increase in average lumbar vertebral bone density (P less than 0.05 in each instance).
2 context sentences(design, population, supporting numbers)
Summary · context
To test this hypothesis, we studied 21 healthy men from 61 to 81 years old who had plasma IGF-I concentrations of less than 350 U per liter during a six-month base-line period and a six-month treatment period that followed.
Summary · context
During the treatment period, 12 men (group 1) received approximately 0.03 mg of biosynthetic human growth hormone per kilogram of body weight subcutaneously three times a week, and 9 men (group 2) received no treatment.
Report a problemFND-0235595203
04HumanNon-randomized trialEfficacy outcome
In older men, human GH increased lumbar vertebral bone density by 1.6 percent (P less than 0.05).
In plain wordsIn older men, human GH increased lumbar spine bone density from baseline by 1.6 percent.
Peptide
HGH (somatotropin)
Outcome
IncreaseLumbar vertebral bone density
Study
n = 12
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
approximately 0.03 mg/kg three times a week · subcutaneous · six monthsAs given in this study (human).
Measurements
Bone density increase
1.6 percent
lumbar vertebrae
Source sentences
Summary
The administration of human growth hormone for six months in group 1 was accompanied by an 8.8 percent increase in lean body mass, a 14.4 percent decrease in adipose-tissue mass, and a 1.6 percent increase in average lumbar vertebral bone density (P less than 0.05 in each instance).
2 context sentences(design, population, supporting numbers)
Summary · context
To test this hypothesis, we studied 21 healthy men from 61 to 81 years old who had plasma IGF-I concentrations of less than 350 U per liter during a six-month base-line period and a six-month treatment period that followed.
Summary · context
During the treatment period, 12 men (group 1) received approximately 0.03 mg of biosynthetic human growth hormone per kilogram of body weight subcutaneously three times a week, and 9 men (group 2) received no treatment.
Report a problemFND-0235595204
05HumanNon-randomized trialEfficacy outcome
In older men, skin thickness increased 7.1 percent during human GH treatment, with P = 0.07.
In plain wordsIn older men, skin thickness increased 7.1 percent from baseline during human GH treatment, with P = 0.07.
Peptide
HGH (somatotropin)
Outcome
No significant changeSkin thickness
Study
n = 12
Comparator
Baseline
Outcome group
Skin and hair · Skin and wound
Studied dose
approximately 0.03 mg/kg three times a week · subcutaneous · six monthsAs given in this study (human).
Measurements
Skin thickness increase
7.1 percent
GH
Source sentences
Summary
Skin thickness increased 7.1 percent (P = 0.07).
2 context sentences(design, population, supporting numbers)
Summary · context
To test this hypothesis, we studied 21 healthy men from 61 to 81 years old who had plasma IGF-I concentrations of less than 350 U per liter during a six-month base-line period and a six-month treatment period that followed.
Summary · context
During the treatment period, 12 men (group 1) received approximately 0.03 mg of biosynthetic human growth hormone per kilogram of body weight subcutaneously three times a week, and 9 men (group 2) received no treatment.
Report a problemFND-0235595205
06HumanNon-randomized trialEfficacy outcome
In older men, human GH produced no significant change in radius bone density.
In plain wordsIn older men, human GH did not significantly change radius bone density from baseline.
Peptide
HGH (somatotropin)
Outcome
No significant changeRadius bone density
Study
n = 12
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
approximately 0.03 mg/kg three times a week · subcutaneous · six monthsAs given in this study (human).
Source sentences
Summary
There was no significant change in the bone density of the radius or proximal femur.
2 context sentences(design, population, supporting numbers)
Summary · context
To test this hypothesis, we studied 21 healthy men from 61 to 81 years old who had plasma IGF-I concentrations of less than 350 U per liter during a six-month base-line period and a six-month treatment period that followed.
Summary · context
During the treatment period, 12 men (group 1) received approximately 0.03 mg of biosynthetic human growth hormone per kilogram of body weight subcutaneously three times a week, and 9 men (group 2) received no treatment.
Report a problemFND-0235595206
07HumanNon-randomized trialEfficacy outcome
In older men, human GH produced no significant change in proximal femur bone density.
In plain wordsIn older men, human GH did not significantly change upper thigh bone density from baseline.
Peptide
HGH (somatotropin)
Outcome
No significant changeProximal femur bone density
Study
n = 12
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
approximately 0.03 mg/kg three times a week · subcutaneous · six monthsAs given in this study (human).
Source sentences
Summary
There was no significant change in the bone density of the radius or proximal femur.
2 context sentences(design, population, supporting numbers)
Summary · context
To test this hypothesis, we studied 21 healthy men from 61 to 81 years old who had plasma IGF-I concentrations of less than 350 U per liter during a six-month base-line period and a six-month treatment period that followed.
Summary · context
During the treatment period, 12 men (group 1) received approximately 0.03 mg of biosynthetic human growth hormone per kilogram of body weight subcutaneously three times a week, and 9 men (group 2) received no treatment.
Report a problemFND-0235595207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.